Home
|
About us
|
Editorial board
|
Search
|
Ahead of print
|
Current issue
|
Archives
|
Submit article
|
Instructions
|
Subscribe
|
Contacts
|
Advertise
|
Reader Login
Search Article
Advanced search
Users Online: 496
Export selected to
Endnote
Reference Manager
Procite
Medlars Format
RefWorks Format
BibTex Format
Access statistics : Table of Contents
2016| January-February | Volume 20 | Issue 1
Online since
December 21, 2015
Archives
Previous Issue
Next Issue
Most popular articles
Most cited articles
Show all abstracts
Show selected abstracts
Export selected to
Viewed
PDF
Cited
REVIEW ARTICLES
Diabetes insipidus: The other diabetes
Sanjay Kalra, Abdul Hamid Zargar, Sunil M Jain, Bipin Sethi, Subhankar Chowdhury, Awadhesh Kumar Singh, Nihal Thomas, AG Unnikrishnan, Piya Ballani Thakkar, Harshad Malve
January-February 2016, 20(1):9-21
DOI
:10.4103/2230-8210.172273
PMID
:26904464
Diabetes insipidus (DI) is a hereditary or acquired condition which disrupts normal life of persons with the condition; disruption is due to increased thirst and passing of large volumes of urine, even at night. A systematic search of literature for DI was carried out using the PubMed database for the purpose of this review. Central DI due to impaired secretion of arginine vasopressin (AVP) could result from traumatic brain injury, surgery, or tumors whereas nephrogenic DI due to failure of the kidney to respond to AVP is usually inherited. The earliest treatment was posterior pituitary extracts containing vasopressin and oxytocin. The synthetic analog of vasopressin, desmopressin has several benefi ts over vasopressin. Desmopressin was initially available as intranasal preparation, but now the oral tablet and melt formulations have gained significance, with benefits such as ease of administration and stability at room temperature. Other molecules used for treatment include chlorpropamide, carbamazepine, thiazide diuretics, indapamide, clofibrate, indomethacin, and amiloride. However, desmopressin remains the most widely used drug for the treatment of DI. This review covers the physiology of water balance, causes of DI and various treatment modalities available, with a special focus on desmopressin.
[ABSTRACT]
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
[CITATIONS]
[PubMed]
17,538
3,289
16
ORIGINAL ARTICLES
Trimester specific reference intervals for thyroid function tests in normal Indian pregnant women
Tarun Sekhri, Juhi Agarwal Juhi, Reena Wilfred, Ratnesh S Kanwar, Jyoti Sethi, Kuntal Bhadra, Sirimavo Nair, Satveer Singh
January-February 2016, 20(1):101-107
DOI
:10.4103/2230-8210.172239
PMID
:26904477
Context:
Accurate assessment of thyroid function during pregnancy is critical, for initiation of thyroid hormone therapy, as well as for adjustment of thyroid hormone dose in hypothyroid cases.
Aims:
We evaluated pregnant women who had no past history of thyroid disorders and studied their thyroid function in each trimester.
Settings and Design:
86 normal pregnant women in the first trimester of pregnancy were selected for setting reference intervals. All were healthy, euthyroid and negative for thyroid peroxidase antibody (TPOAb). These women were serially followed throughout pregnancy. 124 normal nonpregnant subjects were selected for comparison. Material and methods: Thyrotropin (TSH), free thyroxine (FT4), free triiodothyronine (FT3) and anti-TPO were measured using Roche Elecsys 1010 analyzer. Urinary iodine content was determined by simple microplate method. The 2.5th and 97.5th percentiles were calculated as the reference intervals for thyroid hormone levels during each trimester.
Statistical Analysis:
SPSS (version 14.0, SPSS Inc., Chicago, IL, USA) was used for data processing and analysis.
Results:
The reference intervals for the first, second and third trimesters for the following parameters: TSH 0.09-6.65, 0.51-6.66, 0.91-4.86 µ IU/mL, FT4 9.81-18.53, 8.52-19.43, 7.39-18.28 pM/L and FT3 3.1-6.35, 2.39-5.12, 2.57-5.68 pM/L respectively. Thyroid hormone concentrations significantly differed during pregnancy at different stages of gestation. The pregnant women in the study had median urinary iodine concentration of 150-200 µg/l during each trimester.
Conclusions:
The trimester-specific reference intervals for thyroid tests during pregnancy have been established for pregnant Indian women serially followed during pregnancy using 2.5th and 97.5th percentiles.
[ABSTRACT]
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
[CITATIONS]
[PubMed]
6,172
616
8
Effect of hypothyroidism on female reproductive hormones
Sanjay Saran, Bharti Sona Gupta, Rajeev Philip, Kumar Sanjeev Singh, Sureshrao Anoop Bende, Puspalata Agroiya, Pankaj Agrawal
January-February 2016, 20(1):108-113
DOI
:10.4103/2230-8210.172245
PMID
:26904478
Objective:
Objective was to evaluate reproductive hormones levels in hypothyroid women and impact of treatment on their levels.
Materials and Methods:
A total of 59 women with untreated primary hypothyroidism were included in this prospective study. Venous blood was taken at baseline and after euthyroidism was achieved for measuring serum free thyroxine, free triiodothyronine (FT3), thyroid stimulating hormone (TSH), prolactin (PRL), follicular stimulating hormone (FSH), luteinizing hormone (LH), estradiol (E
2
), testosterone (T), and thyroid peroxidase antibody. Thirty-nine healthy women with regular menstrual cycles without any hormonal disturbances served as controls. The statistical analysis was performed using the Statistical Package for the Social Sciences Version 20 ([SPSS] IBM Corporation, Armonk, NY, USA).
P
< 0.05 was considered statistically significant.
Results:
On an average at diagnosis cases have more serum TSH (mean[M] = 77.85; standard error [SE] = 11.72), PRL (M = 39.65; SE = 4.13) and less serum E2(M = 50.00; SE = 2.25) and T (M = 35.40; SE = 2.31) than after achieving euthyroidism (M = 1.74; SE = 0.73), (M = 16.04; SE = 0.84), (M = 76.25; SE = 2.60), and (M = 40.29; SE = 2.27), respectively. This difference was statistically significant t(58) = 6.48,
P
<0.05; t(58) = 6.49,
P
< 0.05; t(58) = 12.47;
P
<0.05; and t(58) = 2.04,
P
<0.05; respectively. Although average serum FSH(M = 12.14; SE = 0.40) and LH (M = 5.89; SE = 0.27) were lower in cases at diagnosis than after achieving euthyroidism (M = 12.70; SE = 0.40),(M = 6.22; SE = 0.25), respectively, but these differences were statistically insignificant t(58) = 1.61,
P
= 0.11; t(58) = 1.11,
P
= 0.27, respectively.
Conclusion:
The study has demonstrated low E2 and T levels in hypothyroid women which were increased after achieving euthyroidism. Although average serum FSH and LH were increased in hypothyroid women after achieving euthyroidism but this difference was statistically insignificant.
[ABSTRACT]
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
[CITATIONS]
[PubMed]
5,097
627
11
REVIEW ARTICLES
Sodium-glucose cotransporter 2 inhibitors with insulin in type 2 diabetes: Clinical perspectives
Mathew John, Deepa Gopinath, Rejitha Jagesh
January-February 2016, 20(1):22-31
DOI
:10.4103/2230-8210.172268
PMID
:26904465
The treatment of type 2 diabetes is a challenging problem. Most subjects with type 2 diabetes have progression of beta cell failure necessitating the addition of multiple antidiabetic agents and eventually use of insulin. Intensification of insulin leads to weight gain and increased risk of hypoglycemia. Sodium-glucose cotransporter 2 (SGLT2) inhibitors are a class of antihyperglycemic agents which act by blocking the SGLT2 in the proximal tubule of the kidney. They have potential benefits in terms of weight loss and reduction of blood pressure in addition to improvements in glycemic control. Further, one of the SGLT2 inhibitors, empagliflozin has proven benefits in reducing adverse cardiovascular (CV) outcomes in a CV outcome trial. Adding SGLT2 inhibitors to insulin in subjects with type 2 diabetes produced favorable effects on glycemic control without the weight gain and hypoglycemic risks associated with insulin therapy. The general risks of increased genital mycotic infections, urinary tract infections, volume, and osmosis-related adverse effects in these subjects were similar to the pooled data of individual SGLT2 inhibitors. There are subsets of subjects with type 2 diabetes who may have insulin deficiency, beta cell autoimmunity, or is prone to diabetic ketoacidosis. In these subjects, SGLT2 inhibitors should be used with caution to prevent the rare risks of ketoacidosis.
[ABSTRACT]
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
[CITATIONS]
[PubMed]
3,531
1,073
11
Dipeptidyl peptidase-4 inhibitors or sodium glucose co-transporter-2 inhibitors as an add-on to insulin therapy: A comparative review
Awadhesh Kumar Singh, Ritu Singh
January-February 2016, 20(1):32-42
DOI
:10.4103/2230-8210.172278
PMID
:26904466
The gradual decline in β-cell function is inevitable in type 2 diabetes mellitus and therefore, substantial proportions of patients require insulin subsequently, in order to achieve optimal glucose control. While weight gain, hypoglycemia, and fluid retention especially during dose intensification is a known limitation to insulin therapy, these adverse effects also reduce patient satisfaction and treatment adherence. It is also possible that the benefits of intensive control achieved by insulin therapy, perhaps get nullified by the weight gain and hypoglycemia. In addition, improvement in plasma glucose or glycated hemoglobin (HbA1c) itself is associated with weight gain. Notably, studies have already suggested that reduction in body weight by ~3–5%, may allow a significantly better glycemic control. Thus, a class of drugs, which can reduce HbA1c effectively, yet are weight neutral or preferably reduce body weight, could be the most sought out strategy as an add-on therapy to insulin. While sulfonylureas (SUs) are associated with weight gain and hypoglycemia, pioglitazone increases body weigh and fluid retention. Moreover, SUs are not recommended once premix or prandial insulin is commenced. The addition of newer agents, such as glucagon-like peptide-1 receptor agonist to insulin certainly appears to be an effective tool in reducing both HbA1c and body weight as is evident across the studies; however, this approach incurs an additional injection as well as cost. Dipeptidyl peptidase-4 inhibitors (DPP-4I) and sodium-glucose co-transporter-2 inhibitors (SGLT-2I) are other exciting options, as an add-on to insulin therapy primarily because these are oral drugs and do not possess any intrinsic potential of hypoglycemia. Furthermore, these are either weight neutral or induce significant weight loss. This review article aims to comparatively analyze the safety and efficacy of DPP-4I and SGLT-2I, as an add-on therapy to insulin.
[ABSTRACT]
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
[CITATIONS]
[PubMed]
3,304
677
4
ORIGINAL ARTICLES
Dietary fat intake and its association with risk of selected components of the metabolic syndrome among rural South Indians
Sowmya Narasimhan, Lakshmipriya Nagarajan, Ruchi Vaidya, Geetha Gunasekaran, Gayathri Rajagopal, Vijayalakshmi Parthasarathy, Ranjit Unnikrishnan, Ranjit Mohan Anjana, Viswanathan Mohan, Vasudevan Sudha
January-February 2016, 20(1):47-54
DOI
:10.4103/2230-8210.172248
PMID
:26904468
Context:
There is limited literature on the dietary fat intake of rural Indian populations, particularly in relation to the risk of metabolic syndrome (MS).
Aim:
This study aims to assess the dietary fat intake and analyze its association with the risk of selected components of the MS among rural population in the state of Tamil Nadu.
Settings and Design:
Adults (
n
= 27012) ≥20 years of age were recruited from the rural component of the Chennai Urban Rural Epidemiological Study, a cross-sectional study conducted in 42 villages in Kanchipuram District of Tamil Nadu.
Subjects and Methods:
Using a validated food frequency questionnaire, data were obtained on the fat intake among 6907 adults. Anthropometric and clinical measures were collected using standard methods. The components of the MS assessed were abdominal obesity, hypertension, and impaired fasting glucose. All analyses were performed using SPSS software (version 20).
Results:
Prevalence of abdominal obesity, hypertension, and impaired fasting glucose were significantly higher in the highest quintile of fat intake (33%,
P
< 0.001; 39%,
P
= 0.04, and 23.3%,
P
= 0.003, respectively). Highest intake of fat was also significantly associated with risk of abdominal obesity (
P
< 0.001), hypertension (
P
= 0.04), and impaired fasting glucose (
P
= 0.01). Sunflower oil as the main cooking oil was significantly associated with a higher risk of these components of the MS (
P
for trend <0.001) compared to traditional oils and palmolein.
Conclusions:
Higher dietary fat was significantly associated with risk of components of the MS and use of sunflower oil as main cooking oil increased metabolic risk in rural South Indians.
[ABSTRACT]
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
[CITATIONS]
[PubMed]
3,050
502
11
Comparison of efficacy and safety of choline fenofibrate (fenofibric acid) to micronized fenofibrate in patients of mixed dyslipidemia: A randomized, open-label, multicenter clinical trial in Indian population
Piyush Patel, Hanmant Barkate
January-February 2016, 20(1):67-71
DOI
:10.4103/2230-8210.172243
PMID
:26904471
Introduction:
Choline fenofibrate is a newly developed choline salt of fenofibric acid, which is more hydrophilic than fenofibrate. This study was initiated to evaluate the safety and efficacy of choline fenofibrate in comparison to micronized fenofibrate among Indian patients of mixed dyslipidemia.
Methods:
A multicenter, open-label, randomized, active controlled, comparative, parallel group study was conducted at around 10 centers spread all across the country. Mixed dyslipidemia patients (serum triglycerides [TG] levels between 150 and 500 mg/dl), aged 18–70 years and taking stable statin dose for 8 weeks were randomized to choline fenofibrate 135 mg delayed release tablets and micronized fenofibrate 160 mg tablets once daily for 12 weeks. The primary endpoint of the study was percentage change in serum TG level at the end of 12 weeks.
Results:
A total of 226 patients were enrolled in this study, of which 116 patients were administered choline fenofibrate and 110 patients were administered micronized fenofibrate. At the end of 12 weeks, there was a significant reduction in TG level (34.24% in choline fenofibrate group and 38.13% reduction in micronized fenofibrate group). However, the difference between group was not statistically different (
P
= 0.471). Similarly, there was a significant increase in high-density lipoprotein cholesterol at the end of 12 weeks (10% increase in choline fenofibrate group and 9% increase in micronized fenofibrate group); but the difference between the group was not statistically significant (
P
= 0.598). Both the treatment was safe and well tolerated.
Conclusion:
Choline fenofibrate delayed release 135 mg is as safe and effective as 160 mg of micronized fenofibrate in Indian patients with mixed dyslipidemia.
[ABSTRACT]
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
[CITATIONS]
[PubMed]
2,937
499
2
BRIEF COMMUNICATIONS
Newer antidiabetic drugs and calorie restriction mimicry
Sanjay Kalra, Jubbin Jagan Jacob, Yashdeep Gupta
January-February 2016, 20(1):142-146
DOI
:10.4103/2230-8210.172242
PMID
:26904485
De-acceleration of aging and delayed development of age-related morbidity accompanies the restriction of calories (without malnutrition) in laboratory mice, nematodes, yeast, fish, and dogs. Recent results from long-term longitudinal studies conducted on primates have suggested longevity benefits of a 30% restriction of calories in rhesus monkeys as well. Among calorie restricted rhesus monkeys one of the mechanisms for the improvement in lifespan was the reduction in the development of glucose intolerance and cardiovascular disease. Although there are no comparable human studies, it is likely that metabolic and longevity benefits will accompany a reduction in calories in humans as well. However, considering the difficulties in getting healthy adults to limit food intake science has focused on understanding the biochemical processes that accompany calorie restriction (CR) to formulate drugs that would mimic the effects of CR without the need to actually restrict calories. Drugs in this emerging therapeutic field are called CR mimetics. Some of the currently used anti-diabetic agents may have some CR mimetic like effects. This review focuses on the CR mimetic properties of the currently available anti-diabetic agents.
[ABSTRACT]
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
[CITATIONS]
[PubMed]
2,557
558
8
ORIGINAL ARTICLES
Cardiovascular risk factors, micro and macrovascular complications at diagnosis in patients with young onset type 2 diabetes in India: CINDI 2
Bhavana Sosale, Aravind R Sosale, Anjana R Mohan, Prassanna M Kumar, Banshi Saboo, Sai Kandula
January-February 2016, 20(1):114-118
DOI
:10.4103/2230-8210.172277
PMID
:26904479
Context:
Type 2 diabetes mellitus (T2DM) in young adults is increasing in India. Data on the prevalence of cardiovascular (CV) risk factors and complications associated with young-onset T2DM (YOD) at the time of diagnosis of diabetes are limited. This data can aid in aggressive diabetes management, CV risk reduction, and prevention of complications.
Aim:
To determine the prevalence of CV risk factors, micro and macrovascular complications in patients with newly diagnosed YOD. To assess the percentage of patients who require statin therapy based on current American Diabetes Association (ADA) guidelines.
Settings and Design:
This was a retrospective cross-sectional study of 1500 patients with newly detected YOD across seven centers from 2013 to 2015.
Designs and Methods:
Patients were evaluated for complications of diabetes and CV risk factors such as body mass index (BMI), hypertension, dyslipidemia, and smoking.
Statistical Analysis:
Measurements have been presented as mean ± standard deviation; results on categorical measurements have been presented in percentages.
Results:
The mean age, glycated hemoglobin and BMI were 34.7 ± 4.2 years, 9.9 ± 2.4%, and 26.8 ± 4.7 kg/m
2
. Hypertension, dyslipidemia, BMI >23 kg/m
2
, and smoking were presented in 27.6%, 62.4%, 84.2%, and 24%. Diabetic retinopathy, neuropathy, and nephropathy were seen in 5.1%, 13.2%, and 0.9%. Ischemic heart disease, peripheral vascular disease, and stroke were presented in 0.7%, 2%, and 0.1%. As per current guidelines, 95.33% needed statin therapy.
Conclusion:
This study demonstrates that patients with YOD have micro and macrovascular complications at diagnosis. Nearly, every patient required a statin to reduce CV risk. This highlights the importance of screening patients with YOD for CV risk factors and complications of diabetes at the time of diagnosis.
[ABSTRACT]
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
[CITATIONS]
[PubMed]
2,497
596
10
ENDOCRINOLOGY AND GENDER
Presentation of gender dysphoria: A perspective from Eastern India
Debmalya Sanyal, Anirban Majumder
January-February 2016, 20(1):129-133
DOI
:10.4103/2230-8210.172247
PMID
:26904482
Context:
There is paucity of scientific data from India on gender identity disorders (GIDs) or gender dysphoria (GD).
Aims:
To study the clinical, biochemical profile, personality characteristics and family support of GID subjects.
Settings and Design:
A retrospective and cross-sectional study at an endocrine referral center in Kolkata in Eastern India between 2010 and 2015.
Subjects and Methods:
Seventy-three GID subjects who presented to the center were included in the study. Clinical, biochemical profile, personality characteristics (cross-dressing), and family support were investigated. The protocol was presented to the Ethics Committee who felt that given the retrospective nature of the study, informed consent could be dispensed with. GD was diagnosed by Diagnostic and Statistical Manual of Mental Disorders (Fourth Edition).
Statistical Analysis Used:
Unpaired
t
-test has been used to find the significance of study parameters between two groups of patients. Chi-square/Fisher Exact test has been used to find the significance of study parameters on categorical scale between two groups.
Results:
Out of the total 73 patients, 55 (75.34%) patients were male-to-female and remaining 18 (24.66%) were female-to-male. Around 11% of GD subjects practiced cross-dressing. In spite of median age of onset of GD was 9 years, the mean age of GD at presentation was quite late at 25.77 ± 6.25 years due to lack of social and informative support. It is difficult for transgender to express their sexual identity in family or in society as only 10.96% of our GD subjects had family support, leading to delayed presentation and delayed endocrine consultation. This delayed endocrine consultation have accounted for a significant proportion of GD subjects having unplanned and ill-timed castration (16.36%) or mastectomy (16.67%) even by nonmedically qualified person (66.7% of castrated subjects). All GD subjects had normal thyroid stimulating hormone, testosterone, estradiol, and karyotype concordant with their biological sex. No significant differences were demonstrated between any of the studied parameters namely age at presentation, onset-age of GD, hormone profile, family support, and cross-dressing preferences.
Conclusions:
Social taboo and lack of informative, family support leads to delayed medical consultation and have accounted for complexities in presentation indicating a huge need of awareness programs in our country. Social and informative support can be improved by awareness programs, which might lead to an early endocrine evaluation and proper treatment with improved outcomes.
[ABSTRACT]
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
[CITATIONS]
[PubMed]
2,659
401
4
ORIGINAL ARTICLES
Assessment of serum prolactin levels in acute myocardial infarction: The role of pharmacotherapy
Hayder M Al-Kuraishy, Ali I Al-Gareeb, Mohamed S Awad, Sinan B Alrifai
January-February 2016, 20(1):72-79
DOI
:10.4103/2230-8210.172240
PMID
:26904472
Background:
Hyperprolactinemia may reflect neuroendocrine stress reaction against acute coronary syndromes.
Aim:
The aim of the present study was evaluation of the serum prolactin level in the acute myocardial infarction (MI) regarding the current pharmacotherapy in management of MI.
Setting and Design:
Cross-sectional clinical based study.
Subjects and Methods:
This cross-sectional clinical study involved all patients with acute MI in a coronary care unit, a total number of 44 patients (45% males and 55% females) with age ranged from 40 to 75 years. A full history for modifiable risk factors and current therapy with aspirin, clopidogrel and or metformin, all patients are nonsmokers. The anthropometric measurements; for estimations of body mass index (kg/m
2
), electrocardiography was obtained. Fasting blood samples were taken in the morning from all patients and the sera used for estimations of routine investigation and determination of ischemic cardiac biomarkers like cardiac troponin I (cTnI) and serum prolactin level.
Results:
This study shows a significant increase in the serum prolactin in acute MI as compared with the control. In acute MI serum cTnI elevation was correlated with serum prolactin increments. In metformin-treated group, there was a lowest prolactin serum level.
Conclusions:
Serum prolactin level increased in acute MI, and positively correlated with cardiac troponin level and reflects underlying cardiovascular complications.
[ABSTRACT]
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
[CITATIONS]
[PubMed]
2,369
407
2
ENDOCRINOLOGY AND THE ARTS
Goiter in portraits of Judith the Jewish heroine
Davide Lazzeri, Manuel Francisco Castello, Donatella Lippi, George M Weisz
January-February 2016, 20(1):119-122
DOI
:10.4103/2230-8210.172266
PMID
:26904480
Judith was a legendary Hebrew heroine who beheaded the general Holofernes and saved the children of Israel from destruction by the Assyrian army. In the Book of Judith, which is still present in the Catholic and Orthodox Christian Bibles, Judith is presented as an illustrious woman who defeated the enemy using her virtue and fortitude. The present investigation has revealed 24 portraits in which Judith has been depicted with variable grades of thyroid gland enlargement on the scene where she decapitates Holofernes. There is no doubt that the integration of a slight thyroid enlargement in the paintings is a stylistic hallmark that portrays an idealized female beauty with a balanced neck and graceful body. The large extended goiter was probably depicted by the artists as a symbol of a powerful masculine body and her courage, and at the same time, it probably also reflects better anatomic accuracy and knowledge of artists from that period.
[ABSTRACT]
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
[CITATIONS]
[PubMed]
2,200
300
1
ORIGINAL ARTICLES
Celiac autoimmunity in autoimmune thyroid disease is highly prevalent with a questionable impact
Bharat Rakeshkumar Sharma, Ameya S Joshi, Premlata K Varthakavi, Manoj D Chadha, Nikhil M Bhagwat, Pratibha S Pawal
January-February 2016, 20(1):97-100
DOI
:10.4103/2230-8210.172241
PMID
:26904476
Introduction:
The prevalence of autoimmune thyroid disease (AITD) is 10–12% in the general population worldwide. Among various disorders co-existing with AITD, the concomitance of celiac disease (CD) with AITD results in poor absorption of thyroid medications and results in higher doses of the same. Institution of gluten-free diet (GFD) in this cohort helps reduce medication doses.
Aim:
To screen patients with AITD for the presence of celiac autoimmunity (CA).
Materials and Methods:
A total of 280 consecutive patients with AITD attending the thyroid Out-patient Department of a tertiary care hospital were screened for the presence of tissue transglutaminase antibodies (immunoglobulin A tissue transglutaminase). Those with a positive titer (but < 10 times the upper limit of normal underwent upper gastrointestinal endoscopy and duodenal mucosal biopsy for the diagnosis of CD, followed by institution of GFD in confirmed cases.
Results:
Of a total of 280 (182 females and 98 males) patients with AITD screened, 24 (8.6%) turned out to be positive for CA. Of 24 (8.6%), 15 (8.24%) females and 9 (9.18%) males were positive for CA. There was no statistically significant difference in the thyroxine doses required for normalization of thyroid function and the weight of the patients in CA positive and CA negative patients.
Conclusions:
The prevalence of CD in patients with AITD is much greater than in the general population. This forms the basis for screening patients with AITD for presence of CD.
[ABSTRACT]
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
[CITATIONS]
[PubMed]
1,881
379
1
EDITORIALS
Biosimilar insulins: Informed choice for South Asia
Sanjay Kalra, AK Azad Khan, Syed Abbas Raza, Noel Somasundaram, Dina Shrestha, Zafar Ahmed Latif, Sarita Bajaj, Md. Faruque Pathan, Rakesh Sahay, Hajera Mahtab
January-February 2016, 20(1):5-8
DOI
:10.4103/2230-8210.164033
PMID
:26904463
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
[CITATIONS]
[PubMed]
1,757
486
1
ORIGINAL ARTICLES
Need for testing glucose tolerance in the early weeks of pregnancy
Seshiah Veeraswamy, Hema Divakar, Sanjay Gupte, Manjula Datta, Anil Kapur, Balaji Vijayam
January-February 2016, 20(1):43-46
DOI
:10.4103/2230-8210.172238
PMID
:26904467
Aims:
This observational study aims to determine the frequency of occurrence of glucose intolerance in the early weeks of pregnancy.
Materials and Methods:
New World Health Organization 2013 guidelines recommends “A Single Step Procedure”(SSP) as an option for diagnosing gestational diabetes mellitus (GDM). Pregnant women attending 131 prenatal clinics across India for the first time underwent SSP consisting of administration of 75 goral glucose irrespective of the last meal timing and to diagnose GDM with 2 h plasma glucose (PG) value≥7.8 mmol/L (7.8 mmol/L).
Results:
In a cohort of
n
= 11,785, the number of pregnant women who underwent the test in first, second, and third trimesters were 4300, 4632, and 2853, respectively. Documented blood glucose values were available for 9282 pregnant women and in them, diagnosis of GDM was made in 740 (8%). Among them, 233 (31.5%), 320 (43.2%), and 187 (25.3%) were in the first, second and third trimesters, respectively. Positive family history of diabetes (43%) and history of fetal loss in previous pregnancy (27%) was more common in women diagnosed with GDM in the first trimester compared to GDM diagnosed in the second or third trimester.
Conclusion:
Manifestation of GDM in the early weeks of gestation is quite common.
[ABSTRACT]
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
[CITATIONS]
[PubMed]
1,703
409
5
EDITORIALS
Endocrinology, Evidence and Sherlock Holmes
Ambika Gopalakrishnan Unnikrishnan, Sanjay Kalra
January-February 2016, 20(1):1-2
DOI
:10.4103/2230-8210.172290
PMID
:26904461
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
[PubMed]
1,763
336
-
ORIGINAL ARTICLES
Chronic sub-clinical inflammation in the abdominal adipose tissue – Evaluation of inflammatory cytokines and their link with insulin resistance in metabolically obese South Indians: Across-sectional observational study
M Premanath, H Basavanagowdappa, M Mahesh, M Suresh Babu, D Devananda
January-February 2016, 20(1):84-91
DOI
:10.4103/2230-8210.172244
PMID
:26904474
Objective:
To measure the levels of proinflammatory cytokines tumor necrosis factor-alpha (TNF-α), interleukin-6(IL-6), and high-sensitive C-reactive protein (hs-CRP) and the anti-inflammatory cytokine adiponectin (AN) in obese South Indian subjects and to ascertain whether or not a causal role could be ascribed to these cytokines in the development of insulin resistance (IR).
Materials and Methods:
Forty obese and forty nonobese volunteers of both genders were recruited. Parameters such as body mass index (BMI), waist circumference (WC), and blood pressure were evaluated. Fasting blood sugar (FBS), fasting insulin level, hemoglobin A1c (HbA1C), lipid profile, TNF-α, IL-6, hs-CRP, and AN levels were measured. IR was evaluated by homeostatic model assessment-IR method. Abdominal adiposity was measured by ultrasonography. The results were statistically evaluated by appropriate tests.
Results:
BMI, WC, and visceral fat were high in the obese group. Females had higher subcutaneous fat in both groups. HbA1C was marginally high in the obese group (
P
= 0.014). IR was high in all the groups, obese males showing higher values (not significant[NS]). Total cholesterol and low-density lipoprotein were high in the obese group (
P
= 0.028,
P =
0.003). TNF-α was high in obese males (NS), IL-6 was high in both groups, higher in nonobese females (NS), hs-CRP was high in both groups, higher in females of both groups (NS). AN was high in females of both groups (
P
= 0.002).
Conclusions:
In this study on South Indian subjects, proinflammatory cytokines such as IL-6 and hs-CRP, despite being high, did not show any causal correlation either with abdominal obesity or with IR. TNF-α being normal showed some correlation which was inconsistent. Even the anti-inflammatory adipokine, AN did not show any correlation with IR. Cytokines had an inconsistent correlation with the components of metabolic syndrome hence were not useful.
[ABSTRACT]
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
[PubMed]
1,545
296
-
ARJUNAS RECOLLECTIONS
Arjuna's recollections – Part III (or) an endocrine version of the “Motorcycle Diaries”
V Sri Nagesh
January-February 2016, 20(1):123-128
DOI
:10.4103/2230-8210.172271
PMID
:26904481
The ultimate dream of every young student stepping into the hallowed portals of a medical college is to achieve the holy grail of medical education, a DM seat. However, the real battle begins only after the DM seat is won. The residency is a veritable roller coaster ride all through the three years, with the student alternating between exhilaration and despondency, wisdom and foolishness, hope and despair and ecstasy and agony. The long working hours, logistic difficulties, interpersonal conflicts and resource limitations are the anvils on which the callow postgraduates are beaten into shape, to bring to fore, their inner steel. While the DM residency does succeed in shaping the students into capable and empathic healthcare professionals of the highest order, on quite a few occasions, it leaves behind a host of bittersweet memories, that prompt the student to look back often , not with fondness, but with a sense of regret and heartache. Encompassing all these experiences, is an unvarnished first-hand account of my peregrinations as an endocrine resident at Osmania Medical College.
[ABSTRACT]
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
[PubMed]
1,595
241
-
ORIGINAL ARTICLES
Cross-sectional study of serum parathyroid hormone level in high-risk pregnancies as compared to nonpregnant control
JB Sharma, Subhadra Sharma, BR Usha, Manisha Yadav, Sunesh Kumar, AK Mukhopadhyay
January-February 2016, 20(1):92-96
DOI
:10.4103/2230-8210.172288
PMID
:26904475
Objectives:
To note the value of serum parathyroid hormone (PTH) levels in normal and high-risk pregnancies (HRP) in patients attending antenatal visits at All India Institute of Medical Sciences (AIIMS).
Materials and Methods:
This is a cross-sectional study where a total of 282 patients attending Gynecology Outpatient Department at AIIMS, New Delhi were recruited. Among the 282 subjects, 251 were pregnant, and 31 were controls. The serum was tested for serum PTH levels using Beckman coulter access 2 immunoassay.
Results:
The median value of PTH level in pregnant women was 31.6 pg/ml with range being 0.8–505.5 pg/ml in contrast to 45.9 pg/ml with range being 19–102.7 pg/ml in nonpregnant female. This difference was statistically significant (
P
= 0.0012). There was no significant difference in median level of PTH in different age group. Although the median PTH levels were lower in second trimester (25.25 pg/ml) than in first trimester (35.5 pg/ml) and in third trimester (32.4 pg/ml), the difference was not statistically significant. There was no significant difference in PTH level in HRP (median value – 31.6 pg/ml) as compared to low-risk pregnancies (31.5 pg/ml).
Conclusion:
Serum PTH levels are significantly lower during pregnancy as compared to nonpregnant state. However, age, parity, and HRP did not alter PTH level during pregnancy.
[ABSTRACT]
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
[CITATIONS]
[PubMed]
1,550
268
1
Primary hyperparathyroidism: Achanging scenario in India
Sangeeta Jha, Muthukrishnan Jayaraman, Aman Jha, Ratan Jha, Kirtikumar D Modi, Jayant V Kelwadee
January-February 2016, 20(1):80-83
DOI
:10.4103/2230-8210.172237
PMID
:26904473
Introduction:
Primary hyperparathyroidism (PHPT) is largely a symptomaticdisease with varied systemic manifestations, complicated by coexisting Vitamin D(Vit D) deficiency. Increasing awareness, developments in diagnostics, and Vit D supplementation may have an impact on the disease profile of PHPT.
Methods:
Clinical, biochemical, and pathological profile of PHPT presenting to a tertiary care center in South India were compared in two groups separated as per the period of presentation (Group A: January 1994–May 2007 - 51 cases and GroupB: June 2007–January 2015 - 59 cases).
Results:
PHPT has remained a disease of female preponderance with similar age of presentation. It is being diagnosed earlier (mean duration of symptoms prior to diagnosis was 38.7 months in Group A, significantly longer than 26 months in GroupB). Bone pain and metabolic myopathy were the most common presentations (60%) followed by pathological fracture (16%), renal calculi (13%), and pancreatitis (7%). Pathological fractures have become less frequent. Vit D deficiency is still a widespread co-morbidity. Radionuclide scintigraphy is an effective localizing tool, but ultrasound can be an inexpensive and widely available screening modality.
Conclusion:
PHPT still remains asymptomatic disease of bones and stones, although it is being diagnosed early. Greater awareness, Vit D supplementation, and better diagnostic tools have made it a disease with lesser morbidity and effective cure.
[ABSTRACT]
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
[CITATIONS]
[PubMed]
1,431
358
11
Surgery or no surgery: What works best for the kidneys in primary hyperparathyroidism? A study in a multi-ethnic Asian population
Yu Kwang Donovan Tay, Joan Khoo, Manju Chandran
January-February 2016, 20(1):55-61
DOI
:10.4103/2230-8210.172285
PMID
:26904469
Introduction:
Whether parathyroidectomy is more beneficial to renal function when compared to medical therapy or observation in primary hyperparathyroidism (PHPT) is unclear. Neither has this premise been explored in non-Caucasian populations. The estimated glomerular filtration rate (eGFR) threshold below which parathyroid hormone (PTH) levels rise if at all in PHPT has also not been established. We determined if surgery was superior to medical therapy and observation in a multi-ethnic Asian patient population with PHPT and whether there was an eGFR threshold below which PTH levels further increased in them.
Methods:
Retrospective evaluation of patients with PHPT.
Results:
There were 68.6% Chinese, 17.4% Malays, 10.7% Indians, and 3.3% Eurasians. The median (interquartile range) follow-up was 18.0 months (4.5–46.8). At last follow-up, eGFR in the surgical (80 ± 30 ml/min) was higher than the medical (52 ± 32 ml/min) or observation groups (48 ± 33 ml/min);
P
< 0.01. This difference persisted after adjusting for age, gender, ethnicity, pre-intervention eGFR levels, nephrolithiasis, serum calcium, phosphate, urinary calcium, and duration of follow-up;
P
= 0.035. There was no definite eGFR level below which PTH values rose.
Conclusion:
Our study provides compelling evidence that in PHPT, surgery may be associated with a better renal outcome compared to medical management or observation. This has to be confirmed through prospective randomized controlled trials and the reasons for this finding have to be elucidated through functional and histological measures. The finding in our study of a lack of a specific eGFR threshold below which PTH levels further rose challenges the concept of a fixed renal threshold for secondary elevations of PTH in PHPT.
[ABSTRACT]
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
[CITATIONS]
[PubMed]
1,318
349
1
Bone mineral density in young adult women with congenital adrenal hyperplasia
Nishant Raizada, Viveka P Jyotsna, Ashish Datt Upadhyay, Nandita Gupta
January-February 2016, 20(1):62-66
DOI
:10.4103/0971-6580.172283
Background:
There is equipoise regarding the status of bone mineral density (BMD) in patients with congenital adrenal hyperplasia (CAH), where patients need to be on long-term low-dose steroids.
Objective:
We aimed to evaluate BMD at the hip, spine and forearm in women with CAH and compare it to healthy young adult women of the same age range.
Subjects and Methods:
Fifteen adult women with CAH with age ranging from 18 to 40 years (mean ± standard deviation = 27.5 ± 6.2 years) underwent dual-energy X-ray absorptiometry along with laboratory evaluation. BMD at lumbar spine, hip, forearm along with T-scores were measured. Serum total calcium, phosphate, alkaline phosphatase, 25 hydroxy Vitamin D, intact parathyroid hormone, total testosterone, and dehydroepiandrosterone were assayed. History of any fractures in the past was taken. Fifteen healthy women in the same age range were taken as controls for comparison.
Results:
The BMD at hip (0.85 ± 0.02 g/cm
2
) in CAH was significantly lower as compared with controls (0.92 ± 0.03 g/cm
2
,
P
= 0.029). BMD at lumbar spine was also reduced (0.96 ± 0.02 vs. 1.03 ± 0.03,
P
= 0.057). The BMD at forearm was not significantly different between CAH and controls. The mean Vitamin D was 9.8 ng/ml (deficient range). There was no history of fractures in CAH.
Conclusion:
Young adult CAH women had lower BMD at spine and hip than healthy young adult women of the same age range. The forearm BMD was not different from controls. No change in fracture frequency was present. Patients with CAH being treated with steroids are at increased risk of osteopenia, and their bone health needs to be monitored.
[ABSTRACT]
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
1,379
288
-
BRIEF COMMUNICATIONS
Short-term outcomes of type 2 diabetes mellitus patients treated with canagliflozin in real-world setting
Manash P Baruah, Sanjay Kalra
January-February 2016, 20(1):137-141
DOI
:10.4103/2230-8210.172265
PMID
:26904484
Objective:
This study is aimed to evaluate the characteristics, treatment, and outcomes of patients treated with canagliflozin in the real-world setting within the first 4 months of the product's availability in India.
Patients and Methods:
It is a retrospective study with data collected from Indian clinical database. Patients aged 18 and above who were prescribed canagliflozin were included in this study. All the patients were on other antihyperglycemic agents (AHAs) before the initiation of canagliflozin.
Results:
Overall, nine patients were included in the study, and data for these patients with mean duration of follow-up of 16 weeks was analyzed. Mean age was 47.9 years and mean duration of type 2 diabetes was 6.7 years. Among patients with available laboratory data at baseline and follow-up, mean glycosylated hemoglobin A1c (HbA1c) decreased from 9.0% at baseline to 6.8% at follow-up (
P
< 0.005); mean weight reduced from 69.9 kg at baseline to 67.9 kg at follow-up. When compared to baseline, the usage and or dose of other AHAs were reduced during follow-up.
Conclusion:
Canagliflozin after it became available in India, improved all glycemic parameters and also reduced the weight of the type two diabetic patients who were poorly controlled by multiple AHAs.
[ABSTRACT]
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
[CITATIONS]
[PubMed]
1,272
342
3
Endocrine hygiene
Sanjay Kalra, Yashdeep Gupta, Rakesh Sahay
January-February 2016, 20(1):134-136
DOI
:10.4103/2230-8210.172236
PMID
:26904483
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
[CITATIONS]
[PubMed]
1,244
254
2
EDITORIALS
Our journal: Arjuna's choice, Eklavya's voice
Sanjay Kalra, Ambika Gopalakrishnan Unnikrishnan
January-February 2016, 20(1):3-4
DOI
:10.4103/0971-6580.172264
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
934
277
-
LETTER TO THE EDITOR
Turmeric use is associated with reduced goitrogenesis: Thyroid disorder prevalence in Pakistan
Ali Jawa, Ali Jawad, Syed Hunain Riaz, Muhammad Zaman Khan Assir, Javed Akram
January-February 2016, 20(1):147-147
DOI
:10.4103/2230-8210.172246
PMID
:26904486
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
[PubMed]
768
184
-
Feedback
Subscribe
Sitemap
|
What's New
|
Feedback
|
Disclaimer
|
© Indian Journal of Endocrinology and Metabolism | Published by Wolters Kluwer -
Medknow
Online since 10 December, 2010